Fig. 5

In vitro selection of CTX-R gene-modified primary murine hematopoietic cells during myeloid differentiation. Non-sorted genetically modified lin⁻ cells were treated with cytotoxic drugs in mIL-3/h-GCSF supported suspension culture. a-c Representative flow cytometric data are given to show enrichment of gene-marked cells analyzed by GFP reporter gene expression (FL-1). d LV.SFFV.MDR1, LV.SFFV.CDD.2A.MDR1 as well as LV.SFFV.GFP gene-modified cells were treated with daunorubicin monotherapy (n = 3–7), and (e) LV.SFFV.CDD, LV.SFFV.CDD.2A.MDR1 as well as LV.SFFV.GFP transduced cells were treated with Ara-C monotherapy (n = 7–12). f LV.SFFV.CDD.2A.MDR1 as well as LV.SFFV.GFP gene-modified cells were treated with daunorubicin/Ara-C combination therapy (n = 4–6). Data are presented as fold increase in % GFP⁺ cells (non-treated cells = 1) and mean ± SD are given; *p ≤ 0.05/**p ≤ 0.01 denote significant differences compared to untreated cells with the same vector (calculated by ANOVA)